Physician profile
Yaniv Chen
NPI 1710183314
$28,270.51
in general payments reported to CMS, 2019-2025
60 companies · $3,685 in 2025
The $3,685 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,104 · 2020: $2,121 · 2021: $4,134 · 2022: $4,024 · 2023: $3,740 · 2024: $8,462 · 2025: $3,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $4,195 · Travel and Lodging: $384 · Education: $46.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,261.39 |
| Consulting Fee | $4,195.00 |
| Travel and Lodging | $383.84 |
| Education | $46.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $5,658.88 | 2019-2025 | |
| Abbvie INC. | $2,815.12 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $1,939.83 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Novartis Pharmaceuticals Corporation | $1,645.06 | 2019-2025 | |
| Biogen, INC. | $1,470.48 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $1,402.65 | 2020-2025 | Xcopri |
| Genentech USA, INC. | $1,105.54 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $1,028.32 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Amneal Pharmaceuticals LLC | $858.15 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Acadia Pharmaceuticals INC | $850.40 | 2019-2025 | Nuplazid |
| Allergan, INC. | $695.22 | 2019-2022 | |
| Argenx US, INC. | $648.76 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $641.05 | 2019-2025 | Kisunla, Amyvid |
| Lundbeck LLC | $523.04 | 2019-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $509.56 | 2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaniv Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.